Long-term outcomes after face transplantation are rarely reported in the scientific literature. Here we present outcome data of a partial face allograft recipient 10 years after transplantation.
Medical records were reviewed for functional and psychosocial outcomes as well as complications. Histopathologic analyses of autopsy tissues and characterization of skin immune cells were performed.
The patient retained long-term motor and sensory function, though with a noticeable drop in sensory function after year 5. Social reintegration of the patient was marked by reconnection with his family and participation in public social activities. Immunosuppressive therapy consisted of tacrolimus (target levels 6–8 ng/mL after the first year), mycophenolate, and prednisone, while steroids were completely weaned between years 1 and 7. One acute cellular rejection episode of grade II or higher occurred on average per year and led to chronic skin changes (papillary dermal sclerosis with superficial hyalinization, epidermal thinning with loss of rete ridges, perieccrine fibrosis), but the allograft vessels, muscles, adipose tissue, and bone were spared. Allograft skin was characterized by increased number of CD4+ TNF-α/IL17A producing T-cells as compared with native skin. Long-term kidney function was maintained at 60 mL/min estimated glomerular filtration rate. Unfortunately, the preexisting hepatitis C virus infection with liver cirrhosis was resistant to 3 treatments with new direct-acting antivirals and eventually hepatocellular carcinoma developed, causing the patient’s death 10 years after transplantation.
This report suggests that face transplants can maintain their function for at least 10 years. Chronic skin changes can occur independently of allograft vasculopathy.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Five-year follow-up after face transplantation.N Engl J Med. 2019; 380: 2579-2581
- Face transplant: long-term follow-up and results of a prospective open study.Lancet. 2016; 388: 1398-1407
- Face transplantation: partial graft loss of the first case 10 years later.Am J Transplant. 2017; 17: 1935-1940
- Chronic rejection in vascularized composite allotransplantation.Curr Opin Organ Transplant. 2018; 23: 582-591
- Novel immunological and clinical insights in vascularized composite allotransplantation.Curr Opin Organ Transplant. 2019; 24: 42-48
- Chronic rejection of human face allografts.Am J Transplant. 2019; 19: 1168-1177
- Clinicopathological findings of chronic rejection in a face grafted patient.Transplantation. 2015; 99: 2644-2650
- Role of flow magnetic resonance imaging in the monitoring of facial allotransplantations: preliminary results on graft vasculopathy.Int J Oral Maxillofac Surg. 2019; 49: 169-175
- Restoration of facial form and function after severe disfigurement from burn injury by a composite facial allograft.Am J Transplant. 2011; 11: 386-393
- Facial allotransplantation: a 3-year follow-up report.J Plast Reconstr Aesthet Surg. 2013; 66: 1458-1463
- The Banff 2007 working classification of skin-containing composite tissue allograft pathology.Am J Transplant. 2008; 8: 1396-1400
- March1-dependent modulation of donor MHC II on CD103+ dendritic cells mitigates alloimmunity.Nat Commun. 2018; 9: 3482
- and the ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection.N Engl J Med. 2015; 373: 2599-2607
- Retreatment of hepatitis c virus-infected patients with direct-acting antiviral failures.Semin Liver Dis. 2019; 39: 354-368
- and the POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated hcv infection.N Engl J Med. 2017; 376: 2134-2146
- Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation.Transplantation. 2008; 86: 784-790
- Spectrum of cancer risk among US solid organ transplant recipients.JAMA. 2011; 306: 1891-1901
- Codominant role of interferon-γ- and interleukin-17-producing T cells during rejection in full facial transplant recipients.Am J Transplant. 2016; 16: 2158-2171
- IL-1-IL-17 signaling axis contributes to fibrosis and inflammation in two different murine models of systemic sclerosis.Front Immunol. 2018; 9: 1611
- Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts.J Immunol. 2012; 188: 3573-3583
- Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis.J Invest Dermatol. 2011; 131: 677-687
- Utility of sentinel flaps in assessing facial allograft rejection.Plast Reconstr Surg. 2015; 135: 250-258
- Temporal stability of the human skin microbiome.Cell. 2016; 165: 854-866
- Biomarker evaluation of face transplant rejection: association of donor T cells with target cell injury.Mod Pathol. 2014; 27: 788-799
- Vascularized composite allotransplantation: a closer look at the Banff working classification.Transpl Int. 2016; 29: 663-671
- Functional outcomes of face transplantation.Am J Transplant. 2015; 15: 220-233
- Facial nerve regeneration after facial allotransplantation: a longitudinal clinical and electromyographic follow-up of lip movements during speech.J Plast Reconstr Aesthet Surg. 2017; 70: 729-733
- Recognizing emotional expression as an outcome measure after face transplant.JAMA Netw Open. 2020; 3e1919247
- The significance of vascular alterations in acute and chronic rejection for vascularized composite allotransplantation.J Vasc Res. 2019; 56: 163-180
Published online: February 26, 2020
Accepted: January 18, 2020
© 2020 Elsevier Inc. All rights reserved.